SPECIAL EDITION, AUGUST 2012
Clinical Trials Office
I would like to take this opportunity to welcome you back to our Director’s Update newsletter. The last few months have been a time of rapid growth and intense activity at the MCW Cancer Center, resulting in many significant accomplishments, including the opening of the centralized cancer Clinical Trials Office (CTO). This entire Director’s Update is dedicated to the CTO and the hard work of the staff, faculty, departments, and partnerships that built this important resource from the ground up.
Celebrating the opening of the Clinical Trials Office (CTO), the Medical College of Wisconsin (MCW) reinforces its position as the area’s premier cancer research and treatment destination.
Christopher R. Chitambar, MD FACP, Professor of Medicine at the Medical College of Wisconsin, is a member of the Cancer Cell Biology Research Program at the MCW Cancer Center.
With Phase I of the centralized cancer Clinical Trials Office Implementation and Clinical Trials Management Software (CTMS) Project completed on-time and on-budget, project leader Mike Gill has nothing but praise for the CTO team, and the work they’ve completed thus far.
In addition to centralizing cancer clinical trial resources and processes, all National Cancer Institute-Designated cancer centers are required to carefully and consistently track trials from start to finish. As a result, a primary task of the CTO Implementation Project team was to research, select, and specify the best tracking and monitoring software available.
On July 19, 2012, the Clinical Trials Office hosted an open house to showcase the new disease-based model, promote current open trials, and invite faculty to meet CTO leadership and disease-based teams.
Quick facts and information about the new Clinical Trials Office (CTO) at the MCW Cancer Center.
I could not be more proud of each one you and the work you’ve done to design and create our new Clinical Trials Office. Although these last few months have often been challenging, and marked by long hours and lots of hard work, we never stopped doing what we do best—opening and supporting clinical trials.